RxDoctor Payments Data

Janet Corbett, DO

Family Medicine · Russellville, ARNPI 1104838945

Payments from drug & device makers

$342in general payments, 2019–2025

Across 12 payments — averaging $28.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$140
  • Pfizer$46
  • GSK$44
  • AbbVie$38
  • Merck$28
  • Novo Nordisk$28
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$342100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sunovion Pharmaceuticals Inc.2$140
Pfizer3$46
GSK1$44
AbbVie2$38
Merck1$28
Novo Nordisk2$28
AstraZeneca1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$342 in reported general payments places this provider in the 40th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$57,867
Medicare patients
193
Services billed
2,566

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide46$84,257
OzempicSemaglutide37$49,236
FarxigaDapagliflozin Propanediol24$25,404
LinzessLinaclotide35$20,374
EliquisApixaban16$18,240
JardianceEmpagliflozin11$13,072
MyrbetriqMirabegron27$12,230
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$11,431
Combivent RespimatIpratropium/Albuterol Sulfate15$9,230
SymbicortBudesonide/Formoterol Fumarate17$4,060
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$3,019
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$2,298
Gabapentin127$2,266
Atorvastatin Calcium249$1,815
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen76$1,776

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$28$49,23637 claims
AstraZenecaFarxiga, Symbicort$18$29,46441 claims
AbbVieLinzess, Synthroid$38$21,06448 claims
PfizerEliquis$46$18,24016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Russellville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →